About this trial

Through the MALDI-TOF MS platform, explore the proteomics and peptidomics differences of fasting serum/plasma and urine between non pregnant people with normal glucose tolerance test and prediabetes /diabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively; To explore the role of its proteomics and peptidomics differences in the diagnosis of prediabetes and diabetes, and to establish a new method of differential diagnosis by using the omics data and key characteristic peaks to find potential new diagnostic markers.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Oral Glucose Tolerance Test

Treatment groups

2,860 Participants
are divided into 4 treatment groups

Locations

1
Zhujiang Hospital of Southern Medical University510000, GuangzhouGuangdong, China

Sponsors and collaborators

Zhujiang Hospital

Lead sponsor